There are biotech VCs though just fewer of them and the screening process is quite rigorous. You have to get proof of concept in some academic paper first. That being said the AI drug design companies and the transformation of molecular biology with bioinformatics/NGS into more of an engineering paradigm (at least for diagnostics) will definitely change things. I'd expect medical devices to advance first and then new drug development.